Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial-Reference-Cited by-同舟云学术

Correlation between week 24 trastuzumab-dkst response and week 48 progression-free survival: the HERITAGE trial

Published:2021-08 Issue: Volume:58 Page:18-26
ISSN:0960-9776
Container-title:The Breast
language:en
Short-container-title:The Breast

Author:

Rugo Hope S.,Pennella Eduardo J.,Gopalakrishnan Unmesh,Hernandez-Bronchud Miguel^ORCID,Herson Jay,Koch Hans Friedrich,Loganathan Subramanian,Deodhar Sarika,Marwah Ashwani,Manikhas Alexey,Bondarenko Igor,Parra Joseph D.^ORCID,Abesamis-Tiambeng Maria Luisa T.,Akewanlop Charuwan^ORCID,Vynnychenko Ihor,Sriuranpong Virote,Roy Sirshendu^ORCID,Yanez Ruiz Eduardo Patricio,Barve Abhijit^ORCID,Waller Cornelius F.^ORCID

Funder

Viatris Inc

Publisher

Elsevier BV

Subject

General Medicine,Surgery

Reference28 articles.

1. Targeted therapy of cancer: new prospects for antibodies and immunoconjugates;Sharkey;CA Cancer J Clin,2006

2. Monoclonal antibodies in gynecological cancer: a critical point of view;Bellati;Clin Dev Immunol,2011

3. A clinician’s guide to biosimilars in oncology;Rugo;Canc Treat Rev,2016

4. Barriers to the access and use of rituximab in patients with non-Hodgkin’s lymphoma and chronic lymphocytic leukemia: a physician survey;Baer Ii;Pharmaceuticals (Basel),2014

5. Barriers to the use of trastuzumab for HER2+ breast cancer and the potential impact of biosimilars: a physician survey in the United States and emerging markets;Lammers;Pharmaceuticals (Basel),2014

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Assessing MAPPs assay as a tool to predict the immunogenicity potential of protein therapeutics;Life Science Alliance;2023-10-13

2. Cardiotoxicity of HER-2-targeted drugs when combined with other drugs: A systematic review and single-rate meta-analysis;2023-03-24

3. Adverse event reporting of marketed biosimilar and biological monoclonal antibody cancer treatments in the United States;Expert Opinion on Biological Therapy;2023-03-09

4. Evaluation of Biosimilar Trastuzumab MYL-1401O in HER2-Positive Breast Cancer;The American Journal of Managed Care;2022-09-14